In the past few years, we have seen more medications approved by the US FDA for renal indications than at any time in the history of nephrology combined.
Moreover, we estimate that currently, there are more than 100 clinical trials for various renal indications, with their majority being for glomerular disorders such as IgA nephropathy, lupus nephritis, focal segmental glomerulosclerosis, APOL1 mediated kidney disease, minimal change disease, membranous nephropathy, C3 glomerulopathy, immune complex glomerulonephritis, ANCA glomerulonephritis, among others.
With this “Cambrian explosion” in treatment opportunities on the horizon, we are launching "Emerging Therapeutics," an educational series supported through educational grants by Travere Therapeutics and Vertex Pharmaceuticals to provide scientific and clinical information about therapeutics recently approved or on the horizon.
As we seek additional educational grant opportunities to expand this program, we recommend checking this session regularly for updates and additions.
Support for this program
"Emerging Therapeutics" is an educational program supported through educational grants from corporate sponsors and aims to provide scientific and clinical information about therapeutics recently approved or on the horizon (under clinical investigation). GlomCon has developed all content with complete editorial independence from sponsors.
Design and Editorial Team
Dr. Paolo Nicolai So
Dr. Vinay Srinivasan
Dr. Nasim Wiegley
Dr. Edward Kwakyi